⁃ Voluntarily participate in clinical research; Fully understand and be informed of this study and sign the informed consent form;

• Age ≥ 18 and ≤ 75, male or female;

• ECOG physical performance score of 0-2;

• Patients with histologically confirmed squamous or non-squamous advanced non- small cell lung cancer (according to AJCC, 8th edition);

• Patients who tested negative for driver genes after genetic testing;

• Patients who have undergone previous systemic therapy and failed anti-PD-1/PD- L1 immunotherapy;

• Presence of at least one measurable lesion as defined by Recist criteria 1.1;

• Liver function: Total serum bilirubin ≤ 1.5 × ULN; For subjects without liver metastasis, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, and for those with liver metastasis, ALT and AST ≤ 5 × ULN;

• Renal function: Serum creatinine ≤ 1.5 × ULN or creatinine clearance rate ≥ 45 mL/min (using the Cockcroft/Gault formula); Blood routine: Absolute neutrophil count ≥ 1.5 × 109/L, platelet count ≥ 70 × 109/L; Hemoglobin ≥ 80g/L (no blood transfusion or use of hematopoietic stimulating drugs for correction within 7 days before screening) with an expected lifespan of more than 3 months.